We're a medicine company turning science into healing to make life better for people around the world. It all started nearly 150 years ago with a clear vision from founder Colonel Eli Lilly: "Take what you find here and make it better and better." Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing science to solve some of the world's most significant health challenges. General Information and Guidelines: When you engage with us on LinkedIn, you're agreeing to these Community Guidelines: https://e.lilly/guidelines. If you have questions about a Lilly medicine, contact The Lilly Answers Center at 1-800-Lilly-Rx (1-800-545-5979) Monday through Friday, excluding company holidays.
We're tracking Eli Lilly And Company's market expansion
119 signals in the last 90 days.
How Eli Lilly And Company's international expansion compares to its competitors
Eli Lilly And CompanyYouBars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 Eli Lilly And CompanyYou | 0 | 0 | — | 0 | 0 |
Pharmareferent (m/w/d) – Gastroenterologie, Region Aachen, Bonn, Düsseldorf, Neuss, Ratingen, Mönchengladbach, Remscheid, Wuppertal, Gummersbach, Arnsberg, Lüdenscheid
View postingBad Homburg, Hesse, Germany · 2w ago
Associate Director- Legal
View postingGurgaon, Haryana, India · 2d ago
Executive Director - Clinical Research Physician - GPS Medical
View postingSão Paulo, São Paulo, Brazil · 3d ago
New study on keeping weight off
ActiveLosing weight, keeping it off
Active
New study on keeping weight off
ActiveLilly's LIBRETTO-432 Phase III trial showed selpercatinib reduced disease recurrence or death risk by 83% in RET fusion-positive NSCLC patients. Chinese research centers contributed nearly half of global enrollment, positioning China to lead regulatory submission.
FirstBio Therapeutics established a Scientific Advisory Board with former global pharma R&D leaders to advance FB849 immunotherapy and neurodegenerative disease pipeline development.
Caliway Biopharma presented CBL-514 animal study data at ADA 2026, showing combination with GLP-1/RA drugs reduces weight rebound by 2.7 times and liver fat by 106.7% versus monotherapy.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about Eli Lilly And Company's business, markets, and growth signals.
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
© 2026 Pubrio. All rights reserved.
